Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

1703. Bacterial or Fungal Co-Infection in Patients with Mucormycosis

View through CrossRef
Abstract Background There is a growing concern on infections with multiple organisms including fungi in patients with mucormycosis. However, limited data are available on co-infection in patients with mucormycosis. Methods Patients with proven mucormycosis were retrospectively enrolled at a tertiary hospital from July 2009 to January 2019. Proven mucormycosis was defined as positive fungal culture result for mucormycosis from a sterile biopsy specimen and/or histologic evidence of tissue invasion of hyphae with positive mucormycosis immunohistochemistry test result. We reviewed other pathogens isolated from sterile or non-sterile sites before and after 7 days from the biopsy for infected tissue that suggested invasive fungal infection. Results A total of 61 patients with proven mucormycosis were analyzed. The primary site of infection was as follows; lung (n = 38, 62.3%), rhino-sinus (n = 21, 34.4%), and orbito-cerebral (n = 15, 24.6%). Based on sterile culture results, 4 patients (6.6%) had the evidence of co-infection with other fungi including Candida species (from 3 cases; C. albicans from 1, C. glabrata from 1 and C. krusei from 1), A. flavus (1), and F. solani (1), and 23 patients (37.7%) had the evidence of co-infection with bacteria including E. faecium (VRE) (8), P. aeruginosa (5),coagulase-negative staphylococci (5), methicillin-susceptible S. aureus (4) and others. Based on non-sterile culture results, 10 patients (16.4%) had the evidence of co-infection with fungi other than mucormycosis including Aspergillus species (5, A. fumigatus from 1, Aspergillus not fumigatus from 1 and A. oryzae from 1), Candida species (5, C. albicans from 2, C. tropicalis from 2 and C. glabrata from 1), Penicillium species (1), S. cerevisiae (1) and P. jirovecii (1), and 24 patients (39.3%) had evidence of bacterial co-infection including S. maltophilia (5), methicillin-resistant S. aureus (5), E. faecium (VSE) (3), K. pneumonia (3), P. aeruginosa (3), and others. Conclusion Bacterial or fungal co-infections appear to frequently occur as appreciated before in patients with mucormycosis. These data provide us important information to select empirical antifungal and antibacterial agents. Disclosures All authors: No reported disclosures.
Title: 1703. Bacterial or Fungal Co-Infection in Patients with Mucormycosis
Description:
Abstract Background There is a growing concern on infections with multiple organisms including fungi in patients with mucormycosis.
However, limited data are available on co-infection in patients with mucormycosis.
Methods Patients with proven mucormycosis were retrospectively enrolled at a tertiary hospital from July 2009 to January 2019.
Proven mucormycosis was defined as positive fungal culture result for mucormycosis from a sterile biopsy specimen and/or histologic evidence of tissue invasion of hyphae with positive mucormycosis immunohistochemistry test result.
We reviewed other pathogens isolated from sterile or non-sterile sites before and after 7 days from the biopsy for infected tissue that suggested invasive fungal infection.
Results A total of 61 patients with proven mucormycosis were analyzed.
The primary site of infection was as follows; lung (n = 38, 62.
3%), rhino-sinus (n = 21, 34.
4%), and orbito-cerebral (n = 15, 24.
6%).
Based on sterile culture results, 4 patients (6.
6%) had the evidence of co-infection with other fungi including Candida species (from 3 cases; C.
albicans from 1, C.
glabrata from 1 and C.
krusei from 1), A.
flavus (1), and F.
solani (1), and 23 patients (37.
7%) had the evidence of co-infection with bacteria including E.
faecium (VRE) (8), P.
aeruginosa (5),coagulase-negative staphylococci (5), methicillin-susceptible S.
aureus (4) and others.
Based on non-sterile culture results, 10 patients (16.
4%) had the evidence of co-infection with fungi other than mucormycosis including Aspergillus species (5, A.
fumigatus from 1, Aspergillus not fumigatus from 1 and A.
oryzae from 1), Candida species (5, C.
albicans from 2, C.
tropicalis from 2 and C.
glabrata from 1), Penicillium species (1), S.
cerevisiae (1) and P.
jirovecii (1), and 24 patients (39.
3%) had evidence of bacterial co-infection including S.
maltophilia (5), methicillin-resistant S.
aureus (5), E.
faecium (VSE) (3), K.
pneumonia (3), P.
aeruginosa (3), and others.
Conclusion Bacterial or fungal co-infections appear to frequently occur as appreciated before in patients with mucormycosis.
These data provide us important information to select empirical antifungal and antibacterial agents.
Disclosures All authors: No reported disclosures.

Related Results

The Mycelial Mire-Mucormycosis
The Mycelial Mire-Mucormycosis
Mucormycosis is an infrequent, angio-invasive, fatal fungal infection incriminating immunocompromised individuals.Mucormycosis commonly arises due to infection with rapidly progres...
Mucormycosis Research: A global outlook through bibliometric approaches
Mucormycosis Research: A global outlook through bibliometric approaches
Objective. Mucormycosis is a fungal infection in humans where the causative pathogens belong to the order of Mucorales. The fungal pathogens are also known as black fungi based on ...
Mucormycosis and role of clinical pharmacologist
Mucormycosis and role of clinical pharmacologist
Mucormycosis (zygomycosis) is a fungal infection (serious but rare) caused by a group of molds called mucoromycetes and it is considered the third most common invasive fungal disea...
MUCORMYCOSIS IN POSTCOVID ERA: DIAGNOSTIC AND THERAPEUTIC CHALLENGES
MUCORMYCOSIS IN POSTCOVID ERA: DIAGNOSTIC AND THERAPEUTIC CHALLENGES
Background : Mucormycosis, first identified in 1885, has surged in incidence, especially post-COVID-19, primarily affecting immunocompromised individuals such as those with uncontr...
COVID-19 and Mucormycosis
COVID-19 and Mucormycosis
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with a wide range of opportunistic bacterial and fung...
Is mucormycosis an addition to the pandemic spectrum: An observational study
Is mucormycosis an addition to the pandemic spectrum: An observational study
<p><strong>Abstract:</strong></p> <p><strong>Introduction and Objective:</strong><br />A concerning increase in occurrences of...
Mucormycosis in COVID-19 Pandemic
Mucormycosis in COVID-19 Pandemic
Background Coronavirus disease-2019 (COVID-19) has been associated with a wide range of opportunistic fungal infections. Many countries have seen an unprecedented rise in cases of ...
The incidence of Mucormycosis superinfection. A challenge to current Covid-19 pandemic
The incidence of Mucormycosis superinfection. A challenge to current Covid-19 pandemic
Dear madam, the last year emerged COVID-19 disease is a highly transmissible viral infection caused by novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS...

Back to Top